This week on MedTech Global Insights, we dissect the groundbreaking new cybersecurity guidance jointly pushed by the EU and FDA. This isn't just another regulation. it's a paradigm shift that redefines the requirements for all connected medical devices. We explore how this 'secure by design' mandate impacts everything from product development timelines to submission strategies and the hidden operational costs.

For any MedTech company with a device that connects to a network, this episode is critical. We analyze the complexities of aligning with two of the world's most powerful regulatory bodies, especially when their "harmonized" rules contain subtle but costly differences.

**Featured Case:**

Imagine a scaleup company with a revolutionary remote cardiac monitor, just weeks away from their planned FDA and EU submissions. The new guidance forces them back to the drawing board to generate a complete Software Bill of Materials (SBOM) and conduct comprehensive threat modeling. Their launch is now delayed by a full year, jeopardizing their next funding round and market-leader advantage. This is the reality many innovators are facing today.

**Key Questions Answered:**

* How do the new FDA & EU rules redefine 'secure by design' for your device portfolio?

* Is your Software Bill of Materials (SBOM) truly compliant with both US and EU standards?

* What are the three biggest hidden costs in implementing these new cybersecurity protocols?

* Can you still use a single technical file for both FDA and EU submissions under this framework?

* What are the critical differences in post-market surveillance and reporting?

* Could your legacy products be forced off the market by these new requirements?

* How can you build a cybersecurity strategy that accelerates, rather than delays, market access?

For more information, contact us at [email protected] or visit https://pureglobal.com/. Explore our FREE AI tools and medical device database at https://pureglobal.ai/.